Required efficacy for novel therapies in BCG‐unresponsive non‐muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?

Required efficacy for novel therapies in BCG‐unresponsive non‐muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?

Abstract Background Single‐arm trials are currently an accepted study design to investigate the efficacy of novel therapies (NT) in non‐muscle invasive bladder cancer (NMIBC) unresponsive to intravesical Bacillus Calmette‐Guérin (BCG) immunotherapy as randomized controlled trials are either unfeasib...

Full description

Bibliographic Details
Main Authors: Marian S. Wettstein, David Naimark, Thomas Hermanns, Jaime O. Herrera‐Caceres, Ardalan Ahmad, Michael A.S. Jewett, Girish S. Kulkarni
Format: Article
Language:English
Published: Wiley 2020-05-01
Series:Cancer Medicine
Subjects:
BCG vaccine
clinical trial
phase ii
computer simulation
cystectomy
decision support techniques
Online Access:https://doi.org/10.1002/cam4.2980

Internet

https://doi.org/10.1002/cam4.2980

Similar Items